Michael Davis

Professor, Associate Chair for Graduate Studies, Biomedical Engineering Georgia Tech College of Engineering

  • Atlanta GA

Michael Davis researches cardiac regeneration and preservation.

Contact

Georgia Tech College of Engineering

View more experts managed by Georgia Tech College of Engineering

Spotlight

2 min

CRISPR is the genetic game changer – but are we ready?

CRISPR is here to stay – and the daily advances of this technology and stem cell therapy seem to be moving at a near exponential speed. “CRISPR Therapeutics of Zug, Switzerland, reported that one patient with sickle cell anemia and another with beta thalassemia appear to have benefited from the same CRISPR-based intervention for up to 9 months, STAT reports. (The company gave STAT an early look at the data but did not allow outside commenters to see the results.) Before the treatment, both patients required multiple infusions each year of red blood cells. CRISPR Therapeutics, collaborating with Vertex Pharmaceuticals, removed blood stem cells from their bodies and modified them with CRISPR to knock out a gene that shuts down production of fetal hemoglobin. When the edited cells were put back in each patient’s body through a stem cell transplant—which required a toxic chemotherapy to kill their own stem cells—both people produced high levels of fetal hemoglobin and no longer needed transfusions.” November 19 – Science Mag CRISPR and how it will shape the future of genetics, health care and society are the subject of great debate, hope and concern and if you are a journalist covering this topic and need an expert source for insight and perspective – let us help. Dr. Michael Davis researches cardiac regeneration, stem cell therapy and preservation at the Georgia Tech College of Engineering where he also is the Associate Chair for Graduate Studies in Biomedical Engineering. Michael is available to speak to media regarding this topic, simply click on his icon to arrange an interview.

Michael Davis

Media

Social

Areas of Expertise

Stem Cell Therapy
Cardiac Regeneration

Selected Accomplishments

Atlanta Business Chronicle Healthcare Hero Award (Rising Star)

2015

Emory School of Medicine Hidden Gem Award

2015

Fellow of the American Heart Association

2010

Show All +

Education

Emory University School of Medicine

Ph.D.

Pharmacology

2003

Rutgers University

B.A.

Biology

1998

Affiliations

  • Children's Heart Research and Outcomes (HeRO) Center

Patents

Targeted delivery of biological factors using self-assembling peptide nanofibers

20060088510

2005

The present invention is directed to methodology that allows a variety of compounds to be attached to self-assembling peptides using biotin/streptavidin linkages. The peptides can be used to form a biologically compatible membrane that promotes the growth and differentiation of cells. The attached therapeutic agents can be used to promote this process and the gel along with the growing cells can be implanted at a site in vivo where tissue repair is needed. Alternatively, membranes can be used for culturing cells in vitro or can be used for delivering drugs in vivo in the absence of seeded cells.

View more

Selected Articles

Predicting Functional Responses of Progenitor Cell Exosome Potential with Computational Modeling

Stem Cells Translational Medicine

Trac D, Hoffman JR, Bheri S, Maxwell JT, Platt MO, Davis ME.

2019

Congenital heart disease can lead to severe right ventricular heart failure (RVHF). We have shown that aggregated c-kit+ progenitor cells (CPCs) can improve RVHF repair, likely due to exosome-mediated effects. Here, we demonstrate that miRNA content from monolayer (2D) and aggregated (3D) CPC exosomes can be related to in vitro angiogenesis and antifibrosis responses using partial least squares regression (PLSR). PLSR reduced the dimensionality of the data set to the top 40 miRNAs with the highest weighted coefficients for the in vitro biological responses. Target pathway analysis of these top 40 miRNAs demonstrated significant fit to cardiac angiogenesis and fibrosis pathways. Although the model was trained on in vitro data, we demonstrate that the model can predict angiogenesis and fibrosis responses to exosome treatment in vivo with a strong correlation with published in vivo responses. These studies demonstrate that PLSR modeling of exosome miRNA content has the potential to inform preclinical trials and predict new promising CPC therapies.

View more

Using Statistical Modeling to Understand and Predict Pediatric Stem Cell Function

Circulation: Genomic and Precision Medicine

Shoja-Taheri F, George A, Agarwal U, Platt MO, Gibson G, Davis ME

2019

Congenital heart defects are a leading cause of morbidity and mortality in children, and despite advanced surgical treatments, many patients progress to heart failure. Currently, transplantation is the only effective cure and is limited by donor availability and organ rejection. Recently, cell therapy has emerged as a novel method for treating pediatric heart failure with several ongoing clinical trials. However, efficacy of stem cell therapy is variable, and choosing stem cells with the highest reparative effects has been a challenge.

View more

Electrospun Nanofiber-Based Patches for the Delivery of Cardiac Progenitor Cells

ACS Applied Materials & Interfaces

Streeter BW, Xue J, Xia Y, Davis ME

2019

Congenital heart disease is the number one cause of birth defect-related death because it often leads to right ventricular heart failure (RVHF). One promising avenue to combat this RVHF is the use of cardiac patches composed of stem cells and scaffolds. Herein, we demonstrate a reparative cardiac patch by combining neonatal or child c-kit+ progenitor cells (CPCs) with a scaffold composed of electrospun polycaprolactone nanofibers. We examined different parameters of the patch, including the alignment, composition, and surface properties of the nanofibers, as well as the age of the CPCs. The patch based on uniaxially aligned nanofibers successfully aligned the CPCs. With the inclusion of gelatin in the nanofiber matrix and/or coating of fibronectin on the surface of the nanofibers, the metabolism of both neonatal and child CPCs was generally enhanced. The conditioned media collected from both patches based on aligned and random nanofibers could reduce the fibrotic gene expression in rat cardiac fibroblasts, following stimulation with transforming growth factor β. Furthermore, the conditioned media collected from the nanofiber-based patches could lead to the formation of tubes of human umbilical vein endothelial cells, indicating the pro-angiogenic capability of the patch. Taken together, the electrospun nanofiber-based patches are a suitable delivery vehicle for CPCs and can confer reparative benefit through anti-fibrotic and pro-angiogenic paracrine signaling.

View more

Show All +